Tradestie Institutional Equity Comparison Engine

XBIO vs EYEG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XBIO Overall Edge

XBIO Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xenetic Biosciences, Inc. (XBIO) driven by superior Growth & Margin while EYEG counters with relative strength in Momentum & Technical. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus EYEG at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against EYEG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
XBIO N/M vs EYEG N/M Fwd P/E
Growth & Margin Winner XBIO
Op Margin -81.0% vs N/A ยท YoY +12.0% vs N/A
Momentum & Technical Winner EYEG
1Y -44.9% vs -6.4% ยท 52W Pos 4% vs 15%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XBIO NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap $3.6M
1M Return -27.46%
1Y Return -44.88%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 25.0 Fund 56.0 Flow 50.0 Mom 55.0
EYEG US Equity
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap N/A
1M Return +0.42%
1Y Return -6.36%
Forward P/E N/M
Unified AI Score
55.0 / 100 HOLD
Tech 73.0 Fund 61.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XBIO -44.88% EYEG -6.36% Spread: +39.01 pp (EYEG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XBIO TTM Op. Margin: -81.0% EYEG TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs EYEG. Trailing 12-month operating profitability (XBIO -81.0% vs EYEG N/A) and valuation multiples (XBIO N/M vs EYEG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XBIO (5) vs EYEG (3)
Institutional Metric XBIO EYEG Criterion Row Winner
Market Capitalization Scale $3.6M N/A Larger Scale XBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +12.0% N/A Higher Growth XBIO
Operating Margin (TTM) Profitability -81.0% N/A Higher Margin XBIO
Net Profit Margin Profitability -75.9% N/A Higher Margin XBIO
Return on Equity (ROE) Capital Efficiency -47.0% N/A Higher ROE XBIO
52-Week Range Position Momentum 4% ($1โ€“$5) 15% ($33โ€“$36) Stronger Trend EYEG
Beta / 30D Volatility Risk Regime 1.40ฮฒ ยท 99% Vol 0.13ฮฒ ยท 5% Vol Lower Realized Risk EYEG
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 55.0 / 100 (HOLD) Higher Composite EYEG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XBIO vs EYEG Buy Guide
XBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EYEG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EYEG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XBIO nor EYEG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.